The ‘jury is still out’ on the best time to initiate aggressive therapy in patients with psoriatic arthritis, say researchers who carried out a long-term follow-up study on the benefits of early tight disease control. Despite clear advantages shown in patients in a treat-to-target group at 48 weeks, the benefits had not been maintained compared ...
‘Jury still out’ on treat-to-target strategy for psoriatic arthritis
By Emma Wilkinson
10 Sep 2019